Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of DaVita Inc. securities (NYSE:DVA) from August 5, 2015 through October 21, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for DaVita investors under the federal securities laws.
To join the DaVita class action, go to http://rosenlegal.com/cases-1026.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into unnecessary insurance plans in order to maximize profits; (2) DaVita was using American Kidney Fund as a vehicle to facilitate these improper practices; (3) as such, DaVita’s revenues and profits were illegally obtained; (4) in turn, DaVita lacked effective internal controls over financial reporting; and (5) as a result, Defendants’ statements about DaVita’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1026.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
